公开(公告)号：US20050287541A1

公开(公告)日：2005-12-29

申请号：US10947249

申请日：2004-09-23

申请人： Akira Nakagawara ,  Miki Ohira ,  Shin Ishii ,  Takeshi Goto ,  Hiroyuki Kubo ,  Takahiro Hirata ,  Yasuko Yoshida ,  Saichi Yamada

发明人： Akira Nakagawara ,  Miki Ohira ,  Shin Ishii ,  Takeshi Goto ,  Hiroyuki Kubo ,  Takahiro Hirata ,  Yasuko Yoshida ,  Saichi Yamada

IPC分类号： C12M1/34 ,  C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/118

摘要： A microarray for predicting the prognosis of neuroblastoma, wherein the microarray has 25 to 45 probes related to good prognosis, which are hybridized to a gene transcript whose expression is increased in a good prognosis patient with neuroblastoma and are selected from 96 polynucleotides consisting of the nucleotide sequences of Seq. ID No. 1 to 96 or their partial continuous sequences or their complementary strands, and 25 to 45 probes related to poor prognosis, which are hybridized to a gene transcript whose expression is increased in a poor prognosis patient with neuroblastoma and are selected from 104 polynucleotides consisting of the nucleotide sequences of Seq. ID No. 97 to 200 or their partial continuous sequences or their complementary strands.

摘要翻译： 一种用于预测神经母细胞瘤的预后的微阵列，其中所述微阵列具有与良好预后相关的25至45个探针，其与在具有神经母细胞瘤的良好预后患者中表达增加的基因转录物杂交，并且选自96个由核苷酸 序列Seq。 ID No.1至96或其部分连续序列或其互补链，以及与不良预后相关的25至45个探针，其与在具有神经母细胞瘤的不良预后患者中表达增加的基因转录物杂交并选自104个多核苷酸 由Seq的核苷酸序列组成。 ID号97至200或其部分连续序列或其互补链。

公开(公告)号：US07601532B2

公开(公告)日：2009-10-13

申请号：US10947249

申请日：2004-09-23

申请人： Akira Nakagawara ,  Miki Ohira ,  Shin Ishii ,  Takeshi Goto ,  Hiroyuki Kubo ,  Takahiro Hirata ,  Yasuko Yoshida ,  Saichi Yamada

发明人： Akira Nakagawara ,  Miki Ohira ,  Shin Ishii ,  Takeshi Goto ,  Hiroyuki Kubo ,  Takahiro Hirata ,  Yasuko Yoshida ,  Saichi Yamada

IPC分类号： C12M3/00 ,  C12M1/34 ,  C07H21/02 ,  C07H21/04 ,  C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/118

摘要： A microarray for predicting the prognosis of neuroblastoma, wherein the microarray has 25 to 45 probes related to good prognosis, which are hybridized to a gene transcript whose expression is increased in a good prognosis patient with neuroblastoma and are selected from 96 polynucleotides consisting of the nucleotide sequences of SEQ. ID NOs. 1, 5, 6, 14. 16, 17, 19, 22-24, 28, 29, 31, 37, 39, 40, 43, 44, 47-52, 54, 57-60, 62, 64, 65, 67, 68, 72-75, 77, 78, 80-82, 84, 87, 89-91, 94, 100, 103, 112, 113, 118, 120, 129, 130, 132, 136, 138, 142, 144, 145, 148, 150-153, 155, 158-160, 163-165, 169-171, 173, 174, 177, 178, 180-182, 184, 186, 187, 189, 191, 192, 194, 195, 198-200 or their partial continuous sequences or their complementary strands, and 25 to 45 probes related to poor prognosis, which are hybridized to a gene transcript whose expression is increased in a poor prognosis patient with neuroblastoma and are selected from 104 polynucleotides consisting of the nucleotide sequences of SEQ. ID NOs. 2-4, 7-13, 15, 18, 20, 21, 25-27, 30, 32-36, 38, 41, 42, 45, 46, 53, 55, 56, 61, 63, 66, 69-71, 76, 79, 83, 85, 86, 88, 92, 93, 95-99, 101, 102, 104-111, 114-117, 119, 121-128, 131, 133-135, 137, 139-141, 143, 146, 147, 149, 154, 156, 157, 161, 162, 166-168, 172, 175, 176, 179, 183, 185, 188, 190, 193, 196, 197 or their partial continuous sequences or their complementary strands.

摘要翻译： 一种用于预测神经母细胞瘤的预后的微阵列，其中所述微阵列具有与良好预后相关的25至45个探针，其与在具有神经母细胞瘤的良好预后患者中表达增加的基因转录物杂交，并且选自96个由核苷酸 SEQ。 身份证号 1，5，6，14，16，17，19，22-24，28，29，31，37，39，40，43，44，47-52，54，57-60，62，64，65， 67，68，72-75，77，78，80-82，84，87，89-91，94，100，103，112，113，118，120，129，130，132，136，138， 144,145,148,150-153,155,158-160,163-165,169-171,173,174,177,178,180-182,184,186,187,189,191,192,194， 195，198-200或其部分连续序列或其互补链，以及与不良预后相关的25至45个探针，其与在具有神经母细胞瘤的不良预后患者中表达增加的基因转录物杂交，并且选自104个多核苷酸 的SEQ ID NO： 身份证号 2-4，7-13，15，18，20，21，25-27，30，32-36，38，41，42，45，46，53，55，56，61，63，66，69- 71,76,79,83,85,86,88,92,93,95-99,101,102,104-111,114-117,119,121-128,131,133-135,137,139- 141,143,146,147,149,154,156,157,161,162,166-168,172,175,176,179,183,185,188,190,193,196,197或其部分连续序列 或其互补链。

公开(公告)号：US20070281296A1

公开(公告)日：2007-12-06

申请号：US10533158

申请日：2003-10-30

申请人： Akira Nakagawara ,  Miki Ohira

发明人： Akira Nakagawara ,  Miki Ohira

IPC分类号： C12Q1/68 ,  C07H21/04

CPC分类号： G01N33/57484 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158

摘要： Diagnostic agent or kit for the prognosis of neuroblastoma is used to diagnose the prognosis of neuroblastoma (particularly, classifying its progress and determining stage 4s neuroblastoma), which agent or kit comprising a nucleic acid probe, nucleic acid primers, or a nucleic acid microarray utilizing a nucleic acid comprising one sequence selected from the group consisting of nucleic acids set forth in SEQ ID NO:1 to SEQ ID NO:174, a fragment thereof, or a combination of either or both.

摘要翻译： 用于神经母细胞瘤预后的诊断剂或试剂盒用于诊断神经母细胞瘤的预后（特别是对其进展进行分类并确定阶段4s神经母细胞瘤），所述试剂或试剂盒包含核酸探针，核酸引物或核酸微阵列，其利用 包含选自SEQ ID NO：1至SEQ ID NO：174所示核酸的一个序列的核酸，其片段，或其中任一者或两者的组合。

公开(公告)号：US07429451B2

公开(公告)日：2008-09-30

申请号：US10533158

申请日：2003-10-30

申请人： Akira Nakagawara ,  Miki Ohira

发明人： Akira Nakagawara ,  Miki Ohira

IPC分类号： C12Q1/68 ,  C07H21/02

CPC分类号： G01N33/57484 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158

摘要： Diagnostic agent or kit for the prognosis of neuroblastoma is used to diagnose the prognosis of neuroblastoma (particularly, classifying its progress and determining stage 4s neuroblastoma), which agent or kit comprising a nucleic acid probe, nucleic acid primers, or a nucleic acid microarray utilizing a nucleic acid comprising one sequence selected from the group consisting of nucleic acids set forth in SEQ ID NO:1 to SEQ ID NO:174, a fragment thereof, or a combination of either or both.

摘要翻译： 用于神经母细胞瘤预后的诊断剂或试剂盒用于诊断神经母细胞瘤的预后（特别是对其进展进行分类并确定阶段4s神经母细胞瘤），所述试剂或试剂盒包含核酸探针，核酸引物或核酸微阵列，其利用 包含选自SEQ ID NO：1至SEQ ID NO：174所示核酸的一个序列的核酸，其片段，或其中任一者或两者的组合。

公开(公告)号：US20100055691A1

公开(公告)日：2010-03-04

申请号：US12439760

申请日：2007-08-24

申请人： Akira Nakagawara ,  Tian-Ling Liu ,  Tadayuki Koda

发明人： Akira Nakagawara ,  Tian-Ling Liu ,  Tadayuki Koda

IPC分类号： C12Q1/68 ,  G01N33/53

CPC分类号： G01N33/6896 ,  G01N2333/9121 ,  G01N2800/2814

摘要： The objective of the present invention is to provide methods of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis (ALS2). The invention provides a method of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis, comprising a step of assessing a substance that suppresses the expression of Tollip in cells as a therapeutic agent for juvenile familial amyotrophic lateral sclerosis; a method of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis, comprising a step of assessing a substance that promotes migration of Tollip in cells from the cytoplasm to the cell nucleus as a therapeutic agent for juvenile familial amyotrophic lateral sclerosis; and a method of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis, comprising a step of assessing a substance that inhibits the interaction between Tollip and IRAK-1 in cells as a therapeutic agent for juvenile familial amyotrophic lateral sclerosis.

摘要翻译： 本发明的目的是提供筛选青少年家族性肌萎缩性侧索硬化症（ALS2）的治疗剂的方法。 本发明提供一种筛选青少年家族性肌萎缩性侧索硬化症的治疗剂的方法，包括评估抑制作为幼年家族性肌萎缩性侧索硬化症的治疗剂的细胞中Tollip的表达的物质的步骤; 筛选青少年家族性肌萎缩性侧索硬化症的治疗剂的方法，包括评估促进细胞中细胞中Tollip从细胞质迁移到细胞核的物质的步骤，作为青少年家族性肌萎缩性侧索硬化症的治疗剂; 以及筛选用于青少年家族性肌萎缩性侧索硬化症的治疗剂的方法，包括评估抑制细胞中Tollip和IRAK-1之间相互作用的物质作为幼年家族性肌萎缩性侧索硬化症的治疗剂的步骤。

公开(公告)号：US20090269794A1

公开(公告)日：2009-10-29

申请号：US12063347

申请日：2006-08-09

申请人： Akira Nakagawara ,  Keizo Takenaga ,  Shigenobu Mochizuki

发明人： Akira Nakagawara ,  Keizo Takenaga ,  Shigenobu Mochizuki

IPC分类号： C12Q1/02

CPC分类号： C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158

摘要： A screening method comprising the following steps is provided. A step of culturing cells in the presence and in the absence of a test compound, a step of measuring HIF-1α expression in the respective cultured cells, and a step of determining the test compound to be a compound that inhibits onset or progression of familial amyotrophic lateral sclerosis if the HIF-1α expression in the cells cultured in the presence of the test compound is less than the HIF-1α expression in the cells cultured in the absence of the test compound.

摘要翻译： 提供了包括以下步骤的筛选方法。 在存在和不存在测试化合物的情况下培养细胞的步骤，测量各培养细胞中HIF-1α表达的步骤和测定化合物成为抑制家族性发作或进展的化合物的步骤 在受试化合物存在下培养的细胞中HIF-1α表达低于在不存在测试化合物时培养的细胞中的HIF-1α表达，肌萎缩性侧索硬化。

公开(公告)号：US07238796B2

公开(公告)日：2007-07-03

申请号：US10487593

申请日：2002-08-23

申请人： Akira Nakagawara ,  Masahira Hattori ,  Yoshiyuki Sakaki

发明人： Akira Nakagawara ,  Masahira Hattori ,  Yoshiyuki Sakaki

IPC分类号： C07H21/02

CPC分类号： C07K14/47

摘要： Human BMCC1 protein having an amino acid sequence set forth in SEQ ID NO:1 in the Sequence Listing and its variant protein, as well as human BMCC1 gene having a base sequence set forth in SEQ ID NO:2 in the Sequence Listing and its variant gene.

摘要翻译： 具有序列表中SEQ ID NO：1所示的氨基酸序列及其变体蛋白质的人BMCC1蛋白质，以及具有序列表的序列号2所示的碱基序列的人BMCC1基因及其变体 基因。

公开(公告)号：US20060240417A1

公开(公告)日：2006-10-26

申请号：US10502449

申请日：2003-01-23

申请人： Akira Nakagawara

发明人： Akira Nakagawara

IPC分类号： C12Q1/68 ,  C07H21/04

CPC分类号： C07K14/4747 ,  A61K48/00

摘要： Elucidation of the interaction between p73 and ΔNp73 on the genetic and protein level, regulators for p73 or p53 apoptosis-inducing activity, a method of accelerating apoptosis of tumor cells by utilizing the regulators, p53 and p73 transactivation regulators comprising the p73 gene and ΔNp73 gene, nucleic acid pharmaceutical compositions comprising compositions for gene therapy which act as the regulators, and a method of screening for the regulators. By forming a heterooligomer by a substance which binds with ΔNp73 promoter to p73 in an antagonistic manner in tumor cells (for example, nucleic acid including a base sequence which hybridizes to the base sequence listed as SEQ ID NO: 1) to control the promoter activity, it is possible to regulate the apoptosis-inducing activity of p73 and augment apoptosis of the tumor cells.

摘要翻译： 阐明p73和DeltaNp73对遗传和蛋白质水平的相互作用，p73或p53凋亡诱导活性的调节因子，通过利用调节剂加速肿瘤细胞凋亡的方法，包含p73基因和DeltaNp73基因的p53和p73转移激活调节物 ，包含充当调节剂的用于基因治疗的组合物的核酸药物组合物，以及筛选调节剂的方法。 通过在肿瘤细胞（例如包含与SEQ ID NO：1所示的碱基序列杂交的碱基序列的核酸）中以拮抗方式与DeltaNp73启动子结合至p73的物质形成异寡聚体以控制启动子活性 ，可以调节p73的凋亡诱导活性，增加肿瘤细胞的凋亡。

公开(公告)号：US5345416A

公开(公告)日：1994-09-06

申请号：US928442

申请日：1992-08-12

申请人： Akira Nakagawara

发明人： Akira Nakagawara

IPC分类号： G11C17/00 ,  G11C8/12 ,  G11C16/02 ,  G11C16/04 ,  H01L21/8247 ,  H01L27/115 ,  G11C13/00

CPC分类号： H01L27/115 ,  G11C16/0491 ,  G11C8/12

摘要： A non-volatile memory comprises memory cells M arranged in a matrix (MB), word lines (W1 to Wn) for row selection, sub-bit lines (B: B12, B21, B22, B31), sub-column lines (C: C11, C12, C22), a column selection circuit 1, a bit line selection circuit 2, and a column line selection circuit 3. The word lines (W1 to Wn) are used as gates common to the rows of the memory cells M, a group of sub-bit lines B and sub-column lines C is selected by the column selection circuit 1, an even-numbered or odd-numbered sub-bit line B is selected from each group and connected to any one of main bit lines (B1, B2 and B3) by the bit line selection circuit 2, and an even-numbered or odd-numbered sub-column line (C) is selected from each group and connected to any one of main column lines (C1 and C2) by the column line selection circuit 3.

摘要翻译： 非易失性存储器包括以矩阵（MB）排列的存储单元M，用于行选择的字线（W1至Wn），子位线（B：B12，B21，B22，B31），子列线（C ：C11，C12，C22），列选择电路1，位线选择电路2和列线选择电路3.字线（W1至Wn）用作存储单元M的行共用的门 ，通过列选择电路1选择一组子位线B和子列线C，从每组中选择偶数或奇数子位线B，并连接到主位 由位线选择电路2产生的线（B1，B2和B3），并且从每个组中选择偶数或奇数子列线（C），并连接到主列线（C1和C2）中的任何一个 ）通过列线选择电路3。

公开(公告)号：US07985556B2

公开(公告)日：2011-07-26

申请号：US12063381

申请日：2006-08-09

申请人： Akira Nakagawara ,  Toshinori Ozaki

发明人： Akira Nakagawara ,  Toshinori Ozaki

IPC分类号： G01N33/53 ,  G01N33/567

CPC分类号： G01N33/574 ,  G01N33/5011 ,  G01N33/6896 ,  G01N2333/4748 ,  G01N2500/02 ,  G01N2510/00

摘要： Screening methods for determining pro-apoptotic compounds or anti-apoptotic compounds comprise measuring the interaction between p53 and NEDL1 in the presence and in the absence of a test compound, and comparing the strength of interaction between p53 and NEDL1 in the presence and in the absence of the test compound.

摘要翻译： 用于测定促凋亡化合物或抗凋亡化合物的筛选方法包括在存在和不存在测试化合物的情况下测量p53和NEDL1之间的相互作用，并且比较p53和NEDL1在存在和不存在下的相互作用强度 的试验化合物。